Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 237

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Hyperhomocysteinemia in Chronic Renal Disease

BOSTOM, ANDREW G., CULLETON, BRUCE F. · 1999 · Journal of the American Society of Nephrology

Abstract

Cardiovascular disease (CVD) is the major cause of death both in the general population and in patients with end-stage renal disease (ESRD). CVD is responsible for approximately 40% of all deaths in both demographic groups (1, 2). Although the proportion of people dying of cardiovascular causes is similar, the risk of CVD is far greater for patients with ESRD. Even after stratification by age, gender, race, and presence of diabetes, CVD mortality in dialysis patients is 10 to 20 times higher than in the general population (3). Renal transplant recipients (RTR) experience at least twofold increases in the annual death rate from CVD, and fourfold increases in pooled nonfatal and fatal CVD incidence relative to population-based estimates (1, 3,4,5) (Table 1). The excess risk of CVD in chronic renal disease is due in part to a higher prevalence of established arteriosclerotic risk factors, including older age, hypertension, diabetes, dyslipidemia, and physical inactivity (4, 6,7,8). However, unique renal-related risk factors, including hemodynamic and metabolic factors characteristic of chronic renal disease, also likely contribute to this excess CVD risk (4, 6,7,8).Table 1: Arteriosclerotic cardiovascular disease incidence after renal transplantationaProminent among these unique renal-related risk factors are elevated levels of the putatively atherothrombotic sulfur amino acid homocysteine. Homozygous genetic disorders (i.e., the homocystinurias) result in marked hyperhomocysteinemia (total homocysteine [tHcy] levels of 100 to 500 μmol/L) and are clearly associated with precocious atherothrombotic events (9). tHcy-lowering treatment reduces the incidence of such outcomes among these patients (9, 10). In addition, pooled observational studies suggest that mild-to-moderate hyperhomocysteinemia (tHcy levels of 12 to 99 μmol/L) is also a significant risk factor for arteriosclerotic CVD among the general population (11,12,13). However, randomized, controlled clinical trial data confirming these reported associations are unavailable. Moreover, the impact of cereal grain flour fortification with folic acid (14, 15) on plasma tHcy levels within the general population may obfuscate the results from any such trials conducted in the United States. Chronic renal disease patients have an excess prevalence of mild-to-moderate hyperhomocysteinemia, which has been independently linked to their development of CVD outcomes in recent prospective observational studies (16,17,18,19). Accordingly, lowering tHcy levels in patients with chronic renal disease may reduce the excess incidence of arteriosclerotic CVD outcomes. Renal transplant recipients comprise a unique subpopulation for testing this tenable hypothesis. In addition to their excess rate of de novo and recurrent CVD events, RTR also have a high prevalence of hyperhomocysteinemia, which contrasts with other potential target populations with normal renal function (20). Furthermore, their tHcy levels can be “normalized” safely and effectively with combined folic acid, vitamin B12, and vitamin B6 treatment (21). In many ways the renal transplant population is representative of the larger population of patients with chronic renal disease who have not yet reached ESRD (8). As such, should homocysteine-lowering by B vitamin supplementation in RTR reduce the rate of occurrence of CVD events, these findings would likely be generalizable to the much more sizable population of patients with renal insufficiency progressing to ESRD. However, currently there are no data from randomized, controlled trials demonstrating that successful treatment of mild hyperhomocysteinemia actually reduces CVD outcomes in people with chronic renal disease. As such, we do not believe screening or treatment recommendations for mild hyperhomocysteinemia in this patient population can or should be provided. Epidemiology: Determinants of Plasma/Serum Homocysteine Levels, and the Prevalence and Etiology of Hyperhomocysteinemia General Populations Approximately 70 to 80% of circulating plasma/serum tHcy is bound to large proteins (e.g., albumin) (22), the remainder consisting of a “free” acid-soluble fraction, i.e., reduced Hcy (<1%), homocystine disulfide, and the predominant non-protein-bound forms, homocysteine-mixed disulfides (22). Folate, pyridoxal 5′-phosphate (PLP or “active” vitamin B6), and vitamin B12 are the main vitamin cofactors/substrates for homocysteine metabolism (Figure 1). Vitamin B-12 and folate play a critical role in the remethylation of homocysteine to methionine (23). Betaine (trimethylglycine) is another substrate that participates in the remethylation of homocysteine to methionine via a B12/folate-independent reaction (24).Figure 1.: Homocysteine metabolism. Enzyme reactions that are regulated by S-adenosylmethionine (SAM) and 5-methyltetrahydrofolate (Methy-THF) are indicated by large arrows. Open arrows indicate activation, closed arrows indicate inhibition. Enzymes: (1) 5, 10 met

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1681/asn.v104891

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 237

Metadata

Authors
BOSTOM, A. G., & CULLETON, B. F.
Venue
Journal of the American Society of Nephrology
Published
1999-04
Volume
10
Issue
4
Pages
891-900
ISSN
1046-6673 (ISSN-L)
OpenAlex
W2147464835
Cited by
237
References
2
FWCI
13.95
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.